Ustekinumab is safe and effective in ulcerative colitis: 2-year data

New 2-year data from the long-term extension of the phase 3 UNIFI study demonstrates the efficacy and safety of ustekinumab through 2 years of treatment in adults with moderately to severely active ulcerative colitis (UC).

These data, presented by Prof. Bruce Sands (Icahn School of Medicine at Mount Sinai, New York, USA) as a late-breaking data abstract [1], included 399 participants who were in clinical response 8 weeks after receiving a single intravenous (IV) induction dose of ustekinumab and who were then randomised to receive ustekinumab subcutaneous (SC) 90 mg injections every 12 weeks (q12w), ustekinumab SC 90 mg injections every 8 weeks (q8w), or placebo, and who were treated in the long-term extension.

Results showed that the majority of patients were able to sustain remission through week 92 as assessed by symptomatic remission. The percentage of patients receiving ustekinumab SC who were in symptomatic remission between weeks 44 and 92 ranged from 83-90%. Among patients who had achieved clinical remission at maintenance baseline, 69% of patients receiving ustekinumab q8w and 80% of patients receiving ustekinumab q12w maintained symptomatic remission at both weeks 44 and 92. Additional analyses demonstrated that approximately 60% of patients receiving ustekinumab q8w and q12w achieved corticosteroid-free symptomatic remission at week 92 (64.3% and 63.8%, respectively).

Through 2 years, the proportions of patients with adverse events (AEs), serious AEs, and serious infections in the ustekinumab groups were generally comparable with the placebo group. No new safety signals were observed. Ustekinumab has demonstrated a consistent safety profile in UC where trials show the treatment is well tolerated. In the primary randomised population of the Induction and Maintenance studies, a similar proportion of patients in the ustekinumab and placebo groups experienced AEs, serious AEs, infections, and serious infections through to week 44. During the Induction phase, 1 death from an oesophageal varices haemorrhage was reported, and no malignancies, opportunistic infections, or tuberculosis were reported. During the Maintenance phase, no deaths and 2 malignancies other than non melanoma skin cancer (NMSC) were reported (90 mg ustekinumab q8w: colon cancer n=1; 90 mg ustekinumab q12w: papillary renal cell carcinoma n=1). There was one patient-reported NMSC in the 90 mg ustekinumab q12w group (2 squamous cell carcinoma events).

1. Sands BE et al. Efficacy and safety of ustekinumab for ulcerative colitis through 2 years: UNIFI long-term extension. UEG Week Barcelona, Catalonia, Spain, October 19-23, 2019, Abstract LB01.

Posted on 23 October 20198 April 2024